Apellis Pharmaceuticals

NASDAQ: APLS ↗ $41.03 USD ~$3.5B MCAP

#Complement-Mediated Diseases #Paroxysmal Nocturnal Hemoglobinuria (PNH)#Geographic Atrophy (GA) Secondary to AMD #Nephrology #Hematology

Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company developing targeted C3 therapies to inhibit the complement cascade in diseases of hematology, ophthalmology, and nephrology. The company has two FDA-approved C3 inhibitors: Empaveli (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH), and Syfovre for geographic atrophy (GA) secondary to age-related macular degeneration.

Company Info

Sector: Biotechnology / Complement Therapeutics

Headquarters: Waltham, Massachusetts, USA

Founded: 2009

Website: apellis.com/

Upcoming Milestones & Key Dates

Q2 2026

Earnings

Q1 2026 Earnings — Syfovre launch trajectory and Empaveli expansion update

Late 2026

Clinical Trial

Potential label expansion data for pegcetacoplan in additional complement indications

Clinical Development Pipeline

Empaveli (pegcetacoplan)

Target: C3 complement inhibitor

Paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy (C3G) / primary IC-MPGN

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Syfovre (pegcetacoplan)

Target: C3 complement inhibitor (intravitreal)

Geographic atrophy (GA) secondary to age-related macular degeneration

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Pegcetacoplan

Target: C3 complement inhibitor

Cold agglutinin disease and other rare complement-driven conditions

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cedric Francois, M.D., Ph.D.

Co-Founder, President and Chief Executive Officer

Tim Sullivan

Chief Financial Officer

Adam Townsend

Chief Commercial Officer

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →